Trial of Lixisenatide in Early Parkinson's Disease.
Wassilios G MeissnerPhilippe RemyCaroline GiordanaDavid MaltêtePascal DerkinderenJean-Luc HouétoMathieu AnheimIsabelle BenatruThomas BoraudChristine Brefel-CourbonNicolas CarrièreHélène CatalaOlivier ColinJean-Christophe CorvolPhilippe DamierEstelle DellapinaDavid DevosSophie DrapierMargherita FabbriVanessa FerrierAlexandra Foubert-SamierSolène Frismand-KryloffAurore GeorgetChristine GermainStéphane GrimaldiClémence HardyLucie HopesPierre KrystkowiakBrice LaurensRomain LefaucheurLouise-Laure MarianiAna MarquesClaire MarseFabienne Ory-MagneVincent RigalleauHayet SalhiAmandine SaubionSimon R W StottClaire ThalamasClaire ThiriezMélissa TirRichard K WyseAntoine BenardOlivier Rascolnull nullPublished in: The New England journal of medicine (2024)
In participants with early Parkinson's disease, lixisenatide therapy resulted in less progression of motor disability than placebo at 12 months in a phase 2 trial but was associated with gastrointestinal side effects. Longer and larger trials are needed to determine the effects and safety of lixisenatide in persons with Parkinson's disease. (Funded by the French Ministry of Health and others; LIXIPARK ClinicalTrials.gov number, NCT03439943.).